Dr. Thackray is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Research Triangle Park
Suite 100
Durham, NC 27703Phone+1 240-476-2348
Summary
- Seasoned biotechnology executive with experience on both sides of Management-Board interactions for NASDAQ-traded companies. Proven track record leading novel drug development for a broad range of indications including both benign and malignant disease.
Education & Training
National Institutes of Health Clinical CenterResidency, Medical Genetics and Genomics, 1999 - 2000
Children's National HospitalChief Residency, Pediatrics, 1998 - 1999- Children's National HospitalResidency, Pediatrics, 1995 - 1998
George Washington University School of Medicine and Health SciencesClass of 1995
Certifications & Licensure
MD State Medical License 1999 - 2025
DC State Medical License 1996 - 2023- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease Start of enrollment: 2009 May 01
- Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis Start of enrollment: 2010 May 01
- Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 58 citationsPhase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody fo...Leonard E. Weisman, Helen M. Thackray, Joseph A. Garcia-Prats, Mirjana Nesin, Joseph H. Schneider
Antimicrobial Agents and Chemotherapy. 2009-07-01 - 50 citationsPhase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.Daniel J. DeAngelo, Brian A. Jonas, Jane L. Liesveld, Dale L. Bixby, Anjali S. Advani
Blood. 2021-09-20 - 73 citationsA Randomized Study of a Monoclonal Antibody (Pagibaximab) to Prevent Staphylococcal SepsisLeonard E. Weisman, Helen M. Thackray, Robin H. Steinhorn, William F. Walsh, Herbert A. Lassiter
Pediatrics. 2011-08-01
Abstracts/Posters
- A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...Helen M Thackray, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Ov...Helen M Thackray, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Durham Drug Firm BioCryst Receives Orphan Drug Designation for Genetic Disorder TreatmentSeptember 1st, 2022- BCRX Earnings Call for the Period Ending June 30, 2022August 5th, 2022
- BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development OfficerMarch 19th, 2021
- Join now to see all
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
